Close

Add to pipeline

Save Close
You are viewing a limited version of this profile. To access i3's full capabilities.
ViroVet
Save
Company logo (jpg or png)
Parent company
Edit alternate names

Short description

Developer of sustainable virus control solutions for livestock

Founded in 2015
Founded in

Company type Private Public ()
Company type

Industry Group agriculture & food

Sector animals

TRL Range 4-6
TRL 1 Basic research
TRL 2 Technology formulation
TRL 3 Applied research
TRL 4 Small scale prototype
TRL 5 Large scale prototype
TRL 6 Prototype system
TRL 7 Demonstration system
TRL 8 First of a kind commercial system
TRL 9 Full commercial application
TRL Range

Ticker

Headquarters Belgium Leuven, Belgium
Address
City
State
Zip
Country

Parent Companies

Website

Updated by Erwin Blomsma at ViroVet NV on 11/07/2018

Edited by Cleantech Group on 06/30/2022

Traction
  • 0 M&A items
tags
Similar companies
Customers
Save
Add Customer
Date Company
Partnerships
Save
Add Partnership
Date Partner Type
Investment Rounds
Save

IPO INFORMATION

Date

IPO status

IPO Type

Amount

Initial shares

Ticker symbol

Exchange listed

Prospectus URL

Prospectus

Source URL

Source

Description

Cancel Save
Add Investment
Date Investors Type Amount
06/16/2022 (0)
Post-money valuation of
The proceeds from the series C financing will be used to generate solid clinical data with a second vaccine in swine as well as with its BVD antiviral drug in cattle.
 Growth Equity $20,894,000
Delete
Click to add IPO information
Products
Save
Add Product
Product image Name Product status Revenue model Cost metrics

Plasmid launched live attenuated virus vaccines or PLLAV

DNA plasmid that launches a self replicating live attenuated virus

Product Development License of Usage
$/kW (current)
$/kW (projected)
$/kWh (current)
$/kWh (projected)
Delete
You are viewing a limited version of this profile. To access i3's full capabilities.
Back to top

Preload svg text font